ClinicalTrials.gg
CompletedNCT04007601Updated Oct 21, 2026Results posted

Neurostimulation In Adult Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

An interventional study of Active tDCS and Sham tDCS in Acute Lymphoblastic Leukemia, sponsored by St. Jude Children's Research Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by St. Jude Children's Research Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 16, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital — 15 open to participants now, 25 under way, 1 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · St. Jude Children's Research Hospital.

Enrollment
11th of 57
127 · median 42
Started
2019
with 3 others
No phase
12 of 70
3 open now
Registered
49th of 70
by date

Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one is the 11th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2019, is one of 12 with no phase, and was the 49th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

15 of the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

Long-term survivors of ALL are at-risk for neurocognitive impairment, particularly in the area of executive functioning. Relatively limited research has focused on interventions for improving neurocognitive outcomes in long-term survivors of ALL. A promising technique for cognitive enhancement is Transcranial Direct Current Stimulation (tDCS) which differs from conventional cognitive remediation approaches in that it directly stimulates specific brain regions responsible for cognitive processes and activates functional networks similar to those activated during cognitive training.

Primary Objective

To evaluate the efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on direct testing of executive function in survivors of ALL.

Secondary Objectives

  • To evaluate the efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on patient-reported symptoms of executive dysfunction in survivors of ALL.
  • To examine the effects of home-based tDCS paired with remote cognitive training on patterns of regional brain activation as measured by functional magnetic resonance imaging.
  • To examine the effects of home-based tDCS paired with remote cognitive training on white matter integrity and structure as measured by diffusion tensor imaging.
Read the detailed description

Eligible participants will be randomized to receive 1 mA direct current stimulation over the left dorsolateral prefrontal cortex or placebo/sham for 20 minutes. All participants will receive home-based computerized cognitive training. Participants will complete tDCS paired with cognitive training 2 times per week for 6-months.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • Acute Lymphoblastic Leukemia
  • Neurocognitive impairment
  • Executive dysfunction
  • Survivorship
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed treatment for acute lymphoblastic leukemia (ALL) at SJCRH \< 21 years at diagnosis
  • Enrolled on St. Jude Lifetime Cohort Study
  • ≥ 5 years post-diagnosis of ALL
  • ≥ 2 years post-treatment completion deemed to impact the central nervous system.
  • Currently between 18 and 39 years of age
  • English language proficiency
  • Executive dysfunction defined as having an age-adjusted standard score \<16th percentile on Trail Making Test Part B, Controlled Oral Word association Test, or Digit Span Backward
  • Patient-reported executive dysfunction defined as a standard score >84th percentile on the Childhood Cancer Survivor Study Neurocognitive Questionnaire or the Behavior Rating Scale of Executive Function

Exclusion criteria

Exclusion Criteria:

  • Full scale intelligence score \<80
  • Currently taking medication intended to treat neurocognitive impairment (e.g. stimulants)
  • Participated in a past trial of neurostimulation
  • Female who is pregnant or breastfeeding
  • History of seizures within the past year
  • Implanted medical devices or metal in the head
  • History of head injury or a neurodevelopmental disorder (i.e. genetic disorder, hypoxic-ischemic encephalopathy) associated with neurocognitive impairment and unrelated to cancer treatment
  • Currently receiving cancer directed therapy
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Active comparator
    Active tDCS

    Remotely delivered active tDCS + cognitive training

    Device: Active tDCS

  • Placebo comparator
    Sham tDCS

    Remotely delivered sham tDCS + cognitive training

    Device: Sham tDCS

Interventions

  • DeviceActive tDCS

    Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.

  • DeviceSham tDCS

    Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.

06

What researchers measure

Primary outcomes

  1. Direct Testing of Executive Function: Change in Working Memory From Baseline to 6 Months

    Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Digit Span Backward: Digit Span Backward (DSB), from the Digit Span subtest on the WAIS-IV, is a measure of working memory. The number of digits recalled in the longest span is converted to a standard z-score using age-based norms (Mean=0, SD=1). A higher z-score represents a better outcome.

    Time frame: Baseline & 6-month follow-up

  2. Direct Testing of Executive Function: Change in Cognitive Flexibility in Baseline to 6 Months

    Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Trail Making Test Part B (Trails B): This is a timed task that requires a participant to shift his/her attention adaptively and flexibly. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.

    Time frame: Baseline & 6-month follow-up

  3. Direct Testing of Executive Function: Change in Verbal Fluency From Baseline to 6 Months

    Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Controlled Oral Word Association (COWA): This is a task of cognitive/verbal fluency that measures spontaneous production of words beginning with a designated letter or category. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.

    Time frame: Baseline & 6-month follow-up

Secondary outcomes

  1. Change in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months

    Patient reported symptoms of executive dysfunction will be evaluated via the Childhood Cancer Survivor Study Neurocognitive Questionnaire (CCSS-NCQ). The CCSS-NCQ is a 32-item questionnaire evaluating 4 domains of executive function. Z-scores (M=0, SD=1) are calculated using sibling data from the Childhood Cancer Survivor Study. Z-scores apply to all outcome rows (task efficiency, memory, organization, emotion regulation). A higher z-scores represents a better outcome.

    Time frame: Baseline and 6-month follow-up

  2. Change in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months

    Patient reported symptoms of executive dysfunction will be evaluated via the Behavior Rating Inventory for Executive Function - Adult Version (BRIEF-A). The BRIEF-A is a 75-item measure of executive function that provides age- and sex-specific national normative data for nine domains of executive function Z-scores (M=0, SD=1) are reported. A higher z-score represents a better outcome.

    Time frame: Baseline and 6-month follow-up

  3. Change in Structural Brain Connectivity From Baseline to 6 Months

    Structural brain networks are constructed from pair-wise white matter connections between brain regions from diffusion tensor imaging. Streamline density is a normalized (values between 0 and 1), unitless measure that characterizes the amount of white matter connectivity between 2 regions of interest. Higher streamline densities suggest a stronger, more robust structural connection. Here, a positive or negative change in streamline density indicates strengthening or weakening connectivity, respectively.

    Time frame: Baseline and 6-month follow-up

  4. Change in Functional Brain Connectivity From Baseline to 6 Months

    Functional brain networks are constructed from pair-wise correlation of activity in brain regions during resting state functional-MRI. Global efficiency, local efficiency, and clustering coefficient are normalized graph metrics (values between 0 and 1) that characterize brain networks and follow an inverted U-shape. Tendency towards either extreme is associated with disrupted cognitive function. Global and local efficiency are measures of parallel information transfer across the whole brain network and smaller subnetworks respectively. Lower values denote less capacity for parallel information transfer than higher values. Clustering coefficient quantifies the tendency of a network to segregate into neighborhoods. Higher values denote higher segregation.

    Time frame: Baseline and 6-month follow-up

  5. Parameter Estimate (Beta Weight) of Left DLPFC During an N-Back Task From Baseline to 6 Months

    Functional magnetic resonance imaging (fMRI) was used to measure local hemodynamics in a pre-defined region of interest (ROI) in the left dorsolateral prefrontal cortex (Left DLPFC). Individual task-related brain activity was modeled using a General Linear Model (GLM). Reported values represent the group mean parameter estimate (beta weight) extracted from the Left DLPFC ROI for the 2-back (working memory) condition relative to the 0-back (baseline) condition of an N-back task. A higher parameter estimate indicates greater relative neural activation during the working memory condition.

    Time frame: Baseline & 6-month follow-up

07

Results

Posted Oct 16, 2026

Participant flow

A total of 127 patients were enrolled on the study from December 2019 to June 2023. Of the 127, 13 withdrew prior to randomization. 114 were randomized.

Participant flow — Overall Study
MilestonePlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Started5559
Completed3848
Not completed1711
Withdrew: Lost to follow-up32
Withdrew: Physician decision149

Outcome measures

PrimaryDirect Testing of Executive Function: Change in Working Memory From Baseline to 6 Months

Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Digit Span Backward: Digit Span Backward (DSB), from the Digit Span subtest on the WAIS-IV, is a measure of working memory. The number of digits recalled in the longest span is converted to a standard z-score using age-based norms (Mean=0, SD=1). A higher z-score represents a better outcome.

Time frame:
Baseline & 6-month follow-up
Reported as:
Mean · Z-score
Direct Testing of Executive Function: Change in Working Memory From Baseline to 6 Months
Z-scorePlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Direct Testing of Executive Function: Change in Working Memory From Baseline to 6 Months0.23 ± 0.650.31 ± 0.79
PrimaryDirect Testing of Executive Function: Change in Cognitive Flexibility in Baseline to 6 Months

Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Trail Making Test Part B (Trails B): This is a timed task that requires a participant to shift his/her attention adaptively and flexibly. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.

Time frame:
Baseline & 6-month follow-up
Reported as:
Mean · Z-score
Direct Testing of Executive Function: Change in Cognitive Flexibility in Baseline to 6 Months
Z-scorePlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Direct Testing of Executive Function: Change in Cognitive Flexibility in Baseline to 6 Months0.98 ± 1.2640.74 ± 0.96
PrimaryDirect Testing of Executive Function: Change in Verbal Fluency From Baseline to 6 Months

Efficacy of home-based transcranial direct current stimulation (tDCS) paired with remote cognitive training on neurocognitive functioning in long- term survivors of ALL. The measures were analyzed to compare changes in neurocognitive performance from baseline to 6 months between active treatment and placebo groups. The unit of measure is a standardized z-score with a mean of 0 and a standard deviation of 1. A higher z-score represents a better outcome. Controlled Oral Word Association (COWA): This is a task of cognitive/verbal fluency that measures spontaneous production of words beginning with a designated letter or category. Age-based standardized z-scores are calculated (Mean=0, SD=1). A higher z-score represents a better outcome.

Time frame:
Baseline & 6-month follow-up
Reported as:
Mean · Z-score
Direct Testing of Executive Function: Change in Verbal Fluency From Baseline to 6 Months
Z-scorePlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Direct Testing of Executive Function: Change in Verbal Fluency From Baseline to 6 Months0.25 ± 0.540.19 ± 0.77
SecondaryChange in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months

Patient reported symptoms of executive dysfunction will be evaluated via the Childhood Cancer Survivor Study Neurocognitive Questionnaire (CCSS-NCQ). The CCSS-NCQ is a 32-item questionnaire evaluating 4 domains of executive function. Z-scores (M=0, SD=1) are calculated using sibling data from the Childhood Cancer Survivor Study. Z-scores apply to all outcome rows (task efficiency, memory, organization, emotion regulation). A higher z-scores represents a better outcome.

Time frame:
Baseline and 6-month follow-up
Reported as:
Mean · Z-score
Change in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months
Z-scorePlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
NCQ - Task Efficiency-0.11 ± 1.020.01 ± 1.05
NCQ - Memory0.17 ± 1.280.09 ± 1.19
NCQ - Organization0.01 ± 0.63-0.26 ± 1.09
NCQ - Emotion Regulation0.18 ± 0.890.05 ± 0.87
SecondaryChange in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months

Patient reported symptoms of executive dysfunction will be evaluated via the Behavior Rating Inventory for Executive Function - Adult Version (BRIEF-A). The BRIEF-A is a 75-item measure of executive function that provides age- and sex-specific national normative data for nine domains of executive function Z-scores (M=0, SD=1) are reported. A higher z-score represents a better outcome.

Time frame:
Baseline and 6-month follow-up
Reported as:
Mean · Z-score
Change in Patient-Reported Symptoms of Executive Functioning From Baseline to 6 Months
Z-scorePlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Global Executive Composite-0.34 ± 0.68-0.27 ± 0.86
Inhibition-0.38 ± 0.62-0.14 ± 0.90
Self-Monitoring-0.17 ± 0.63-0.08 ± 0.87
Shift-0.31 ± 0.87-0.21 ± 0.92
Emotional Control-0.18 ± 0.71-0.17 ± 0.86
Initiation-0.34 ± 0.84-0.24 ± 1.01
Working Memory-0.25 ± 0.81-0.50 ± 1.08
Planning-0.31 ± 0.89-0.09 ± 0.83
Task Monitoring-0.26 ± 0.70-0.27 ± 0.89
Organization of Materials-0.25 ± 0.57-0.16 ± 0.87
Behavior Regulation Index-0.30 ± 0.64-0.18 ± 0.89
Metacognition Index-0.32 ± 0.73-0.28 ± 0.86
SecondaryChange in Structural Brain Connectivity From Baseline to 6 Months

Structural brain networks are constructed from pair-wise white matter connections between brain regions from diffusion tensor imaging. Streamline density is a normalized (values between 0 and 1), unitless measure that characterizes the amount of white matter connectivity between 2 regions of interest. Higher streamline densities suggest a stronger, more robust structural connection. Here, a positive or negative change in streamline density indicates strengthening or weakening connectivity, respectively.

Time frame:
Baseline and 6-month follow-up
Reported as:
Mean · Normalized streamline density
Change in Structural Brain Connectivity From Baseline to 6 Months
Normalized streamline densityPlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Difference in Frontostriatal Connections (Left)0.1161 ± 0.3603-0.1410 ± 0.3483
Difference in Frontostriatal Connections (Right0.0828 ± 0.4248-0.0295 ± 0.2849
SecondaryChange in Functional Brain Connectivity From Baseline to 6 Months

Functional brain networks are constructed from pair-wise correlation of activity in brain regions during resting state functional-MRI. Global efficiency, local efficiency, and clustering coefficient are normalized graph metrics (values between 0 and 1) that characterize brain networks and follow an inverted U-shape. Tendency towards either extreme is associated with disrupted cognitive function. Global and local efficiency are measures of parallel information transfer across the whole brain network and smaller subnetworks respectively. Lower values denote less capacity for parallel information transfer than higher values. Clustering coefficient quantifies the tendency of a network to segregate into neighborhoods. Higher values denote higher segregation.

Time frame:
Baseline and 6-month follow-up
Reported as:
Mean · Normalized metric (range: 0-1)
Change in Functional Brain Connectivity From Baseline to 6 Months
Normalized metric (range: 0-1)Placebo Comparator: Sham tDCSActive Comparator: Active tDCS
Global Efficiency change0.0043 ± 0.01070.0039 ± 0.0107
Local Efficiency chnage-0.0060 ± 0.0220-0.0109 ± 0.0222
Clustering Coefficient change-0.0105 ± 0.0447-0.0188 ± 0.0545
SecondaryParameter Estimate (Beta Weight) of Left DLPFC During an N-Back Task From Baseline to 6 Months

Functional magnetic resonance imaging (fMRI) was used to measure local hemodynamics in a pre-defined region of interest (ROI) in the left dorsolateral prefrontal cortex (Left DLPFC). Individual task-related brain activity was modeled using a General Linear Model (GLM). Reported values represent the group mean parameter estimate (beta weight) extracted from the Left DLPFC ROI for the 2-back (working memory) condition relative to the 0-back (baseline) condition of an N-back task. A higher parameter estimate indicates greater relative neural activation during the working memory condition.

Time frame:
Baseline & 6-month follow-up
Reported as:
Mean · beta weight
Parameter Estimate (Beta Weight) of Left DLPFC During an N-Back Task From Baseline to 6 Months
beta weightPlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
Left DLPFC at baseline.6772 ± .3486.5634 ± .4124
Left DLPFC at follow-up0.6340 ± 0.4446.7727 ± 0.3941

Adverse events

Collected over Adverse events were surveyed weekly, with symptoms reported for the two prior weekly stimulation sessions. starting at baseline (study enrollment) up to 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Comparator: Sham tDCS1/38 (2.6%)1/38 (2.6%)37/38 (97.4%)
Active Comparator: Active tDCS1/48 (2.1%)1/48 (2.1%)47/48 (97.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
AnxietyPsychiatric disorders1/380/48
PainGeneral disorders0/381/48
InfectionInfections and infestations0/381/48
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlacebo Comparator: Sham tDCSActive Comparator: Active tDCS
HeadacheNervous system disorders22/3833/48
Difficulty sleepingGeneral disorders19/3826/48
FatigueGeneral disorders16/3819/48
Drowsiness during the dayGeneral disorders14/3820/48
Poor concentrationPsychiatric disorders15/3818/48
Dry skinSkin and subcutaneous tissue disorders11/3818/48
PainGeneral disorders9/3815/48
ItchingSkin and subcutaneous tissue disorders9/3814/48
Sleeping too muchGeneral disorders9/3814/48
AnxietyPsychiatric disorders8/3813/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Comparator: Sham tDCSActive Comparator: Active tDCSTotal
Mean32.72 ± 5.5732.33 ± 6.0632.50 ± 5.82
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Comparator: Sham tDCSActive Comparator: Active tDCSTotal
Female192443
Male192443
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Comparator: Sham tDCSActive Comparator: Active tDCSTotal
Hispanic or Latino3811
Not Hispanic or Latino354075
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo Comparator: Sham tDCSActive Comparator: Active tDCSTotal
Race — Black or African American6511
Race — White314071
Race — Other134
08

Study locations

1 site
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2023, 42 months.

Results were first posted in Oct 2026, 3 years 3 months after primary completion.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 42 months is above that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jul 5, 2019
StartActual
Dec 12, 2019
Primary completionActual
Jun 21, 2023
CompletionActual
Jun 21, 2023
Results first posted
Oct 16, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 16, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedDirect Testing of Executive Function: Change in Working Memory from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline & 6-month follow-up
  • EditedDirect Testing of Executive Function: Change in Cognitive Flexibility in baselineBaseline to 6 monthsMonthsTime frame: Baseline & 6-month follow-up
  • EditedDirect Testing of Executive Function: Change in Verbal Fluency from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline & 6-month follow-up
Oct 16, 2026
Secondary outcomes
4 edited, 1 added
What changed in the outcomes
  • EditedChange in Patient-Reported Symptoms of Executive Functioning from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
  • EditedChange in Patient-Reported Symptoms of Executive Functioning from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
  • EditedChange in Structural Brain Connectivity from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
  • EditedChange in Regional Brian Activation from baselineFunctional Brain Connectivity From Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
  • AddedParameter Estimate (Beta Weight) of Left DLPFC During an N-Back Task From Baseline to 6 MonthsTime frame: Baseline & 6-month follow-up
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Results posted
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedDirect Testing of Executive Function: Change in Working Memory from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline & 6-month follow-up
    • EditedDirect Testing of Executive Function: Change in Cognitive Flexibility in baselineBaseline to 6 monthsMonthsTime frame: Baseline & 6-month follow-up
    • EditedDirect Testing of Executive Function: Change in Verbal Fluency from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline & 6-month follow-up
    Secondary outcomes 4 edited, 1 added
    What changed in the outcomes
    • EditedChange in Patient-Reported Symptoms of Executive Functioning from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
    • EditedChange in Patient-Reported Symptoms of Executive Functioning from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
    • EditedChange in Structural Brain Connectivity from baselineFrom Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
    • EditedChange in Regional Brian Activation from baselineFunctional Brain Connectivity From Baseline to 6 monthsMonthsTime frame: Baseline and 6-month follow-up
    • AddedParameter Estimate (Beta Weight) of Left DLPFC During an N-Back Task From Baseline to 6 MonthsTime frame: Baseline & 6-month follow-up
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04007601
Responsible party
Sponsor
First posted
Jul 5, 2019
Start date
Dec 12, 2019
Primary completion
Jun 21, 2023
Completion
Jun 21, 2023
Results posted
Oct 16, 2026
Last update
Oct 21, 2026

Study contacts

Tara Brinkman, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion